Orchid Pharmaceuticals - Orchid Chemicals,pharmaceutical,cephalosporin,bulk drug,formulations,nutraceutical,orchid pharmaceuticals,research & development,pharmaceutical company,alendronate sodium tablets,new drug discovery,cefixime tablets,nimesulide dispersible tablets,amoldipine tablets,new drug delivery systems,quality manufacturing facilities,amlodipine atenolol tablets,sildenafil citrate tablets,ISO 9002,ISO 14001,investors, annual report,careers pharmaceutical,careers research & development,novel drug delivery systems,cefpodoxime proxetil tablets,quality control pharmaceutical formulations,pharmaceutical research,contract manufacture,bulk drug contract manufacture,formulations contract manufacture,contract research,state-of -the art R&D,lisinopril tablets,calcitriol soft gel capsules

Orchid Chemicals & Pharmaceuticals Ltd

Unaudited Financial Results for the year ended June 30, 2001

Sl No

Particulars

Three months ended
June 30, 2001
(Unaudited)

Three months ended
June 30, 2000
(Unaudited)

Year Ended
March 31,2001
(Audited)

Sales and Operating Income

8887.28

8783.74

37124.92

Other Income

1.94

33.83

131.22

Total Expenditure

6554.05

6350.59

27450.85

a) Decrease/(Increase) in Stock in trade

(125.26)

(210.59)

(3698.66)

b) Consumption of raw materials

4478.61

4449.84

21074.17

c) Staff Cost

521.94

451.08

2188.42

d) Other Expenditure

1678.76

1660.26

7886.92

Interest and Finance Charges

789.04

728.41

3043.20

Depreciation

824.35

819.50

3116.31

Profit (+) / Loss (-) before Tax (1+2-3-4-5)

721.78

919.07

3645.78

Provision for Taxation

Nil

70.04

Net Profit (6-7)

721.78

919.07

3575.74

Paid- up Equity Share Capital (Face value of Rs. 10 each)

2799.92

2,799.92

Reserves excluding Revaluation Reserves

36964.65

Basic Earnings per Share (Rs.)

2.58*

3.28*

12.77

Aggregate of Non-Promoter shareholding

- Number of equity shares of Rs.10/- each

23319637

- Percentage of shareholding

83.29

*EPS is for the period (not annualised )

Allotment Committee of the Board of Directors at its meeting held on May 23, 2001 has allotted Foreign Currency Convertible Bonds to M/s. International Finance Corporation, Washington for US$ 20 million.
Shri A R Hegde has been inducted on the Board as Whole-time Director and CEO - Formulations on May 31, 2001.
The above financial results were taken on record by the Board of Directors at its meeting held on Thursday, July 26,2001.

Place : Chennai
Date : 26-07-2001

For and on behalf of the Board

K.Raghavendra Rao
Managing Director